Clinical Trial Update: SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating SYS6002 versus standard chemotherapy for recurrent or metastatic cervical cancer, with the study currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• SYS6002

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Cervical Cancer | Phase 3 | Status: NOT_YET_RECRUITING